ProCE Banner Activity

Phase III RESONATE-2: Frontline Ibrutinib vs Chlorambucil in Elderly Patients With CLL

Slideset Download
Conference Coverage
In this phase III trial that enrolled elderly treatment-naive patients with CLL, ibrutinib was associated with significant reductions in risk of progression and death vs chlorambucil.

Released: December 12, 2015

Expiration: December 10, 2016

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Millennium Takeda

Seagen